Dantrium IV recalled over particulate matter in three lots

Knight Therapeutics Inc. has recalled three lots of Dantrium Intravenous (dantrolene sodium for injection) after particulate matter was found in the affected lots, according to a Health Canada notice posted Oct. 19.

The recall covers 20-milligram vials of the powder for solution, DIN 01997572, from lots 80681, 82413 and 91579. The notice did not list expiry dates.

It is a Type I recall with national distribution, carried out at the level of healthcare establishments. The notice, which is aimed at the general public, healthcare providers and industry, lists the recall under ID RA-82808. The Montreal-based company is the recalling firm.

The notice does not describe a specific health risk. It advises anyone with health concerns to consult a healthcare provider and to contact the recalling firm with questions. People who experience side effects or have other safety complaints are asked to report them to Health Canada.

The full notice is on the Recalls and Safety Alerts site.

Health Canada has issued other drug recalls recently, including Bayer lots of Claritin, Aleve and Flintstones.

If you find reporting like this useful, consider supporting Canada News Media, an independent Canadian newsroom with no corporate parent.